How will omicron surges fare in the face of different vaccination rates—and how will it compare to the delta surge? Advisory Board's Sebastian Beckmann details why vaccine rates won't stop states from experiencing an omicron surge in hospitalizations, but they could shorten the duration of the surge.

As the highly contagious omicron variant continues to drive a surge in cases, scientists are starting to see signs that the variant may soon hit its peak in the United States—although they caution that the situation will remain serious even if there is a rapid decline in cases.

More Americans are now social distancing, self-quarantining, and cutting down on eating out and visiting family and friends than in previous months, largely in response to the omicron variant's spread throughout the United States, according to a recent poll from Axios and Ipsos.

Pfizer is seeking to manufacture up to 100 million doses of an omicron-specific vaccine booster by late spring—and its CEO says it's making at least some doses "at risk," meaning Pfizer could be stuck absorbing the costs of any unused vaccine.

After purchasing a new car in 2002, a man in good health who previously had no history of headaches began experiencing bouts of severe, persistent headaches—a condition that still baffles doctors after nearly 20 years, Sandra Boodman writes for the Washington Post.

New York will no longer conduct active outreach for individuals who test positive for Covid-19, in today's bite-sized hospital and health industry news from California, New York, and Washington.